Overview of Pfizer Medicines
Pfizer Inc. develops, manufactures, and markets a broad portfolio of prescription medicines and vaccines across oncology, immunology, rare diseases, internal medicine, and primary care. Its products include small-molecule drugs, biologics, biosimilars, and vaccines, sold in more than 160 countries. Pfizer generates billions of dollars in annual revenue from blockbuster drugs such as Eliquis, Paxlovid, Ibrance, and Prevnar family vaccines, with a growing focus on oncology and immunology as core strategic pillars. The company also invests heavily in pipeline therapies targeting cardiometabolic, rare genetic, and neuroscience diseases, with a history of large acquisitions and licensing deals to expand its therapeutic areas.
Pfizer’s medicines are prescribed by hospitals, specialty pharmacies, and primary care providers worldwide, supported by a global commercial organization and established manufacturing sites. The company operates through two main business segments: Primary Care and Specialty Care and Oncology, with the latter now representing a significant and growing share of total revenue. Pfizer also supplies generic and biosimilar products through its Greenstone division, aiming to expand access to lower-cost versions of key therapies. Recent pipeline launches and approvals continue to reshape the portfolio, with new oncology combinations, immunology treatments, and long-acting injectables entering the market.
Key Pfizer Medicines by Therapeutic Area
Oncology
Pfizer’s oncology portfolio includes targeted therapies and immuno-oncology drugs such as Braftovi (encorafenib), Mektovi (binimetinib), and the CDK4/6 inhibitor Ibrance (palbociclib), which remains one of the company’s highest-revenue products. The company also markets Xtandi (enzalutamide) for prostate cancer and Talzenna (talazoparib) for BRCA-mutated breast cancer, with ongoing clinical development of antibody-drug conjugates and next-generation kinase inhibitors.
Recent approvals and launches in oncology have strengthened Pfizer’s position in the competitive cancer market, with combination regimens and expanded indications driving new patient starts. The company’s pipeline includes candidates in lung, colorectal, and hematologic malignancies, supported by partnerships and internal research focused on biomarker-driven therapies.
Immunology and Inflammation
In immunology, Pfizer markets Enbrel (etanercept), a leading treatment for rheumatoid arthritis, psoriasis, and other autoimmune conditions, along with newer agents such as Rinvoq (upadacitinib) and Cibinqo (abrocitinib) for atopic dermatitis. The company also supplies Xeljanz (tofacitinib) for rheumatoid arthritis and ulcerative colitis, with a focus on differentiated efficacy and safety profiles in crowded markets.
Pfizer’s immunology strategy emphasizes biosimilar launches and expanded indications for existing brands, aiming to capture market share as patents expire on originator biologics. The company continues to invest in next-generation anti-inflammatory and immune-modulating therapies, targeting unmet needs in difficult-to-treat patient populations.
Vaccines and Specialty Products
Vaccines
Pfizer is a major producer of vaccines, including Prevnar 13 and Prevnar 20 for pneumococcal disease, as well as the COVID-19 vaccine Comirnaty, developed with BioNTech. The company also markets vaccines against influenza, meningococcal disease, and pneumococcal infections, with a strong presence in both adult and pediatric immunization programs worldwide.
Vaccine revenue remains a critical part of Pfizer’s business, with COVID-19 vaccine sales contributing significantly to recent financial results, as reported by Pfizer Inc. The company continues to invest in next-generation vaccine technologies, including mRNA platforms, to broaden its infectious disease portfolio and prepare for future public health threats.
Specialty and Rare Disease Medicines
Pfizer’s specialty portfolio